Rheumatoid Arthritis, Systemic Lupus Erythematosus, Healthy Participants
Conditions
Keywords
Heart rate variability, Deep breathing, Transcutaneous vagus nerve stimulation, Vagus nerve stimulation, Breathing exercises
Brief summary
This interventional study aims to investigate the effect of deep breathing (DB) and transcutaneous electrical vagus nerve stimulation (tVNS) on heart rate variability (HRV) in healthy participants and patients with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). HRV is used as a surrogate measure of vagal nerve tone. The study consists of three sub-projects: Sub-project 1: To compare the effect of one session of DB and one session of non-invasive auricular tVNS on vagal nerve tone measured by HRV in healthy participants and in patients with RA and SLE. The hypotheses is that DB has a similar effect on HRV as non-invasive electrical tVNS. Sub-project 2: A dose-response study in healthy participants comparing the effect of 5, 15 and 30 minutes of DB on HRV. The hypothesis was that HRV increases as a function of the number of minutes the DB is performed in healthy participants. Sub-project 3: To investigate the effect of the optimal dose found in sub-project 2 in patients with RA and SLE measured by HRV, and to investigate its reproducibility by doing it twice.The hypothesis was that HRV increases after DB in patients with RA and SLE, and the effect is reproducible. In all three sub-projects the washout period will be investigated by measuring HRV three times after the intervention. We hypothesise that the effect of DB and tVNS on HRV decreases over time.
Interventions
DEVICENon-invasive auricular electrical transcutaneous vagus nerve stimulation
A NEMOS ® stimulator (Cerbomed, Erlangen, Germany) is used for transcutaneous auricular vagus nerve stimulation. This is a handheld battery driven stimulator which stimulates conca in the outer ear. It stimulates in a serie of small electrical impulses with a pulse width at 250 us and a frequency at 25 Hz for 30 minutes in a cycle for 30 seconds on and 30 seconds off to avoid habituation. It is previously indicated that a stimulation intensity at 0,5 mA, 1 mA or 1,5 mA does not cause a significant chance in HRV, thus 0,5 mA is used in this study.
OTHERDeep breathing
The participant is first verbally introduced to the breathing exercises, and then to the visually cue (animation), which the participant have to follow throughout the session.
Sponsors
Aalborg University
Aalborg University Hospital
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
Sub-project 1: Randomized crossover study Sub-project 2: Randomized parallel Sub-project 3: Single groupe
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
Yes
Inclusion criteria
* Men and women in the age range from 18 years to 85 years old. * For subproject 1 and 3 the participants must be diagnosed with either rheumatoid arthritis or systemic lupus erythematosus. * Must sign and date informed consent.
Exclusion criteria
* Lacking ability to make or understand informed consent. * Medical history with psychiatric or psychological conditions which the person in charge of the research estimates will affect the participants ability to participate in the study. * Furthermore participants with severe mental illness will be excluded due to the fact that severe mental illness cause decreased heart rate variability. * Pregnancy. * Addict or prior addict defined as abuse of hash, opioids or other euphoriant drugs. * Known atrial fibrillation or atrial flutter. * Known chronic lung disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Heart rate variability root mean square of successive R-R intervals (RMSSD) | HRV is measured with five ECG recordings, each lasting 5 min. Two measurements with 5 minutes apart are made just prior to the 30 minutes of deep breathing/tvns. Three measurements are made after the intervention, separated by 7,5 minutes each. | Heart rate variability is used as a surrogate measure of vagus nerve activity. The primary outcome is changes in the HRV-parameter RMSSD |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Heart rate variability standard deviation of the R-R intervals (SDNN) and pairs of successive R-R intervals that differ more than 50 milliseconds divided by the total number of R-R intervals (PNN50) | HRV is measured before and after 30 minutes of deep breathing/tvns. | Heart rate variability is used as a surrogate measure of vagus nerve activity - change in PNN50, SDNN |
Countries
Denmark
Contacts
Primary ContactSalome Kristensen, MD, PhD
Outcome results
None listed